+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Therapeutics for Women's Health: Technologies and Global Markets

  • ID: 3743712
  • Report
  • January 2022
  • Region: Global
  • 258 Pages
  • BCC Research

FEATURED COMPANIES

  • Abbvie Inc.
  • Asahi Kasei
  • Bayer AG
  • Daiichi Sankyo Co. Ltd.
  • Eli Lilly and Co.
  • Gilead Sciences Inc.

Report Scope

This report is an analytical business tool that comprehensively evaluates the global market for women’s health therapeutics. The format of the study is organized around the following topics -






  • Detailed study around women’s diseases, such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and PCOS.
  • Disease incidence and prevalence.
  • Regulatory structure of pharmaceutical industry.
  • Market characterization, unmet need, market size and segmentation.
  • Market drivers and restraints.
  • Detailed market projections through 2026.
  • Competition and market shares.
  • Pricing and reimbursement.
  • Marketed and pipeline (R&D) products along with description, regulatory status, and clinical trials.
  • Observations and conclusions regarding the future of market for women’s health therapeutics.
  • Profiles of market participants and associations.

 


Report Includes

  • 58 data tables and 56 additional tables
  • An overview of the global market and technologies for women's health therapeutics
  • Estimation of the market size and analyses of global market trends, with data from 2018, 2019, 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
  • Detailed study around women’s diseases such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and polycystic ovary syndrome (PCOS); their historical background, stages, symptoms, risk factors and genetic factors, diagnosis, and treatment, etiology, pathophysiology, epidemiology, and economic burden
  • Discussion on aging and women’s health disorders, women & sexual health such as female sexual arousal disorder, female orgasmic disorder, and vaginismus and relation between infertility and cancer
  • Coverage of regulatory structure, pricing, and reimbursement scenarios; marketed and pipeline (R&D) products, and clinical trials
  • Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
  • Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies
  • Comprehensive company profiles of the leading players of the industry, including Roche, Eli Lilly, Pfizer, AstraZeneca, Novartis, Amgen, and Merck
Frequently Asked Questions about the Global Therapeutics for Women Health Market

What is the estimated value of the Global Therapeutics for Women Health Market?

The Global Therapeutics for Women Health Market was estimated to be valued at $54.4 Billion in 2021.

What is the growth rate of the Global Therapeutics for Women Health Market?

The growth rate of the Global Therapeutics for Women Health Market is 5.4%, with an estimated value of $70.8 Billion by 2026.

What is the forecasted size of the Global Therapeutics for Women Health Market?

The Global Therapeutics for Women Health Market is estimated to be worth $70.8 Billion by 2026.

Who are the key companies in the Global Therapeutics for Women Health Market?

Key companies in the Global Therapeutics for Women Health Market include Abbvie Inc., Amgen Inc., Asahi Kasei, Astrazeneca plc, Bayer AG, Bristol, Myers Squibb, Daiichi Sankyo Co. Ltd. and Eli Lilly and Co..
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbvie Inc.
  • Asahi Kasei
  • Bayer AG
  • Daiichi Sankyo Co. Ltd.
  • Eli Lilly and Co.
  • Gilead Sciences Inc.

Chapter 1 Introduction
  • Study Goals and Objectives
  • What's New in this Update?
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials


Chapter 2 Summary and Highlights
Chapter 3 Overview of Technologies and Global Markets
  • Disease Overview and Definitions
  • Historical Background
  • Market Driving Factors and Opportunities
  • Aging Female Population
  • Government Involvement and Increased Funding
  • Increasing Awareness Regarding Women's Disorders and Treatments
  • Market Restraints
  • Poor Diagnosis
  • Availability of Alternate Treatment Options and Lifestyle Changes
  • Unavailability of Novel Treatments
  • High Treatment Cost of Osteoporosis
  • Opportunities
  • Rising Female Population in Asia-Pacific
  • Increased Demand for Technology Innovation
  • Mergers and Acquisitions


Chapter 4 Impact of COVID-19 Pandemic
  • Implications on Women's Health and Diagnosis
  • Implications on Cancer Treatment
  • Impact on Oncology Pharmaceuticals Market


Chapter 5 Pipeline Assessment and Analysis
  • Women's Health Therapeutics: Key Clinical Trial Developments
  • List of Drugs in Pipeline
  • Overview of Osteoporosis Drug Development Pipeline
  • Late-stage Pipeline Drugs


Chapter 6 Regulatory Structure
  • Overview of Regulations
  • U.S.
  • Canada
  • Europe
  • Japan


Chapter 7 Market Breakdown by Women’s Health Disorder
  • Introduction
  • Menopause-Related Diseases
    • Overview
    • Symptoms
    • Risk Factors
    • Epidemiology and Economic Burden
    • Diagnosis
    • Treatments
    • Market Size and Forecast

  • Postmenopausal Osteoporosis
    • Overview
    • Epidemiology and Economic Burden
    • Diagnosis
    • Treatments
    • Market Size and Forecasts

  • Endometriosis
    • Overview
    • Epidemiology and Economic Burden
    • Diagnosis
    • Treatments
    • Market Size and Forecasts

  • Polycystic Ovary Syndrome
    • Overview
    • Etiology
    • Reducing PCOS Risk
    • Epidemiology and Economic Burden
    • Disease Symptoms and Risk Factors
    • Diagnosis
    • Treatments
    • Market Size and Forecasts

  • Breast Cancer
    • Overview
    • Market Size and Forecasts



Chapter 8 Market Breakdown by Region
  • Introduction
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia-Pacific
  • Rest of the World
  • South America
  • Middle East and Africa


Chapter 9 Pricing and Reimbursement
  • Overview of Pricing and Reimbursement
  • U.S.
  • Canada
  • Europe
  • Japan


Chapter 10 Competitive Landscape and Key Developments
  • Market Players and Strategies
  • Blockbuster Breast Cancer Pharmaceutical Brands
  • Patent Analysis
  • List of Key Patents
  • Key Developments
  • Mergers and Acquisitions
  • Development of Innovative Products/Novel Product Launch
  • Agreements, Collaborations and Partnerships
  • Key Products


Chapter 11 Company Profiles
  • Abbvie Inc.
  • Amgen Inc.
  • Asahi Kasei
  • Astrazeneca plc
  • Bayer AG
  • Bristol-Myers Squibb
  • Daiichi Sankyo Co. Ltd.
  • Eli Lilly and Co.
  • Eisai
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Merck Kgaa
  • Novartis AG
  • Novo Nordisk
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.


Chapter 12 Conclusions: Outlook for Women’s Health Therapeutics
  • Major Developments to Influence Market
  • Therapeutic Developments
  • Demographic and Economic Trends
  • Income Growth in Emerging Markets
  • Future Outlook


Chapter 13 Appendix A: Glossary of TermsChapter 14 Appendix B: Industry and Professional Organizations
Chapter 15 Appendix C: Acronyms Used in This Report
  • Acronyms Used in This Report


List of Tables
Summary Table A : Global Market for Women’s Health Therapeutics and Technologies, by Disease Area, Through 2026
Summary Table B : Global Market for Women’s Health Therapeutics, by Region, Through 2026
Table 1 : Life Expectancy at Birth, Both Sexes Combined, by Region, 1990-2030 (Estimated)
Table 2 : Recent M&A Deals in the Global Market for Women’s Health Therapeutics, 2019-2021
Table 3 : Novel Breast Cancer Drug Approvals
Table 4 : Selected New Breast Cancer Drugs in Late Stages of Clinical Development
Table 5 : Pipeline Molecules, Endometriosis
Table 6 : Pipeline Molecules, Uterine Fibroids
Table 7 : Pipeline Molecules, All Other Indications
Table 8 : Pipeline Molecules, Osteoporosis
Table 9 : Elagolix Snapshot
Table 10 : Vilaprisan Snapshot
Table 11 : Evenity Snapshot
Table 12 : Relugolix Snapshot
Table 13 : Proellex Snapshot
Table 14 : Esmya Snapshot
Table 15 : TX-004HR Snapshot
Table 16 : TX-001HR Snapshot
Table 17 : Global Market for Women’s Health Therapeutics and Technologies, by Disease Area, Through 2026
Table 18 : FDA Approved Estrogen-only Medicines
Table 19 : FDA Approved Progestin-Only Medicines
Table 20 : FDA Approved Combination, Estrogen and Progestin Medicines
Table 21 : FDA Approved Combination Estrogen and Hormone Medicines
Table 22 : Vagifem (10mcg), Patent Expiration
Table 23 : Global Market for Menopause Therapeutics, by Region, Through 2026
Table 24 : Prolia/XGEVA (Denosumab) Patent Expiration
Table 25 : Global Market for Postmenopausal Osteoporosis Therapeutics, by Region, Through 2026
Table 26 : Global Market for Endometriosis Therapeutics, by Region, Through 2026
Table 27 : Commonly Prescribed Generic Drugs for the Treatment of PCOS
Table 28 : Global Market for PCOS Therapeutics, by Region, Through 2026
Table 29 : TNM Classifications of Breast Cancers
Table 30 : Global Breast Cancer Incidence, 2016-2021
Table 31 : Global Breast Cancer Incidence and Mortality, by Region, 2018
Table 32 : Types of Hormone Therapy for Breast Cancer
Table 33 : Drugs Commonly Used to Treat Breast Cancer
Table 34 : Global Market for Breast Cancer Therapeutics, by Region, Through 2026
Table 35 : Global Market for Women’s Health Therapeutics, by Region, Through 2026
Table 36 : North American Market for Women’s Health Therapeutics, by Country, Through 2026
Table 37 : North American Market for Women’s Health Therapeutics, by Disease Area Through 2026
Table 38 : U.S. Market for Women’s Health Therapeutics, by Disease Area Through 2026
Table 39 : Canadian Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 40 : Mexican Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 41 : European Market for Women’s Health Therapeutics, by Country, Through 2026
Table 42 : European Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 43 : U.K. Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 44 : German Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 45 : French Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 46 : Spanish Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 47 : Italian Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 48 : Rest of the European Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 49 : Asia-Pacific Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 50 : RoW Market for Women’s Health Therapeutics, by Sub-region Through 2026
Table 51 : RoW Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 52 : South American Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 53 : Middle East and African Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 54 : Blockbuster Breast Cancer Pharmaceuticals, by Company Revenue, 2018-2020
Table 55 : Major Women’s Health Therapeutics Pharmaceuticals by Company Revenue, 2020
Table 56 : Global Market Shares of Women’s Health Therapeutics, by Company Revenue, 2020
Table 57 : Patent Review, 2021
Table 58 : Novel Women’s Health Therapeutic Drug Approvals, 2021
Table 59 : Selected New Women’s Health Therapeutic Drugs in Late Stages of Clinical Development
Table 60 : Marketed Products, Postmenopausal Osteoporosis
Table 61 : AbbVie: Oncology Pharmaceutical Revenue, 2018-2020
Table 62 : AbbVie Inc.: Net Revenue, 2017-2020
Table 63 : AbbVie: Oncology Pharmaceutical Product Portfolio
Table 64 : AbbVie Inc.: Marketed Products
Table 65 : AbbVie Inc.: Key Developments, 2021
Table 66 : Allergan plc: Marketed Products
Table 67 : Allergan plc: Net Revenue, 2017-2019
Table 68 : Amgen: Oncology Pharmaceutical Product Portfolio
Table 69 : Amgen: Oncology Pharmaceutical Revenue, 2018-2020
Table 70 : Amgen: Financials, 2014-2020
Table 71 : AstraZeneca: Oncology Pharmaceutical Product Portfolio
Table 72 : AstraZeneca: Oncology Pharmaceutical Revenue, 2018-2020
Table 73 : Bayer AG: Marketed Products
Table 74 : Bayer AG: Oncology Pharmaceutical Product Portfolio
Table 75 : Bayer AG: Oncology Pharmaceutical Revenue, 2018-2020
Table 76 : Bayer AG: Net Revenue, 2018-2020
Table 77 : Bristol-Myers Squibb: Oncology Pharmaceutical Product Portfolio
Table 78 : Bristol-Myers Squibb: Oncology Pharmaceutical Revenue, 2018-2020
Table 79 : Daiichi Sankyo Co. Ltd.: Marketed Products
Table 80 : Daiichi Sankyo Co. Ltd.: Net Revenue 2018-2020
Table 81 : Eli Lilly and Co.: Marketed Osteoporosis Products
Table 82 : Eli Lilly and Co.: Net Revenue, 2018-2020
Table 83 : Eli Lilly and Co.: Oncology Pharmaceutical Product Portfolio
Table 84 : Eli Lilly and Co.: Oncology Pharmaceutical Revenue, 2018-2020
Table 85 : Roche: Oncology Pharmaceutical Product Portfolio
Table 86 : Roche: Oncology Pharmaceutical Revenue, 2018-2020
Table 87 : Gilead Sciences Inc.: Oncology Pharmaceutical Product Portfolio
Table 88 : Gilead Sciences Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 89 : Johnson & Johnson: Oncology Pharmaceutical Product Portfolio
Table 90 : Johnson & Johnson: Oncology Pharmaceutical Revenue, 2018-2020
Table 91 : Johnson & Johnson Services Inc.: Net Revenue, 2017-2020
Table 92 : Merck & Co. Inc.: Marketed Products
Table 93 : Merck & Co. Inc.: Net Revenue, 2017-2019
Table 94 : Merck & Co. Inc.: Oncology Pharmaceutical Product Portfolio
Table 95 : Merck & Co., Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 96 : Merck KGaA Marketed Products
Table 97 : Novartis: Oncology Pharmaceutical Product Portfolio
Table 98 : Novartis: Oncology Pharmaceutical Revenue, 2018-2020
Table 99 : Novo Nordisk: Marketed Products
Table 100 : Novo Nordisk: Net Revenue, 2017-2019
Table 101 : Pfizer Inc.: Oncology Pharmaceutical Product Portfolio
Table 102 : Pfizer Inc.: Women’s Health-Marketed Products, by Indication
Table 103 : Pfizer Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 104 : Pfizer Inc. Net Revenue, 2017-2019
Table 105 : Sanofi: Oncology Pharmaceutical Product Portfolio
Table 106 : Sanofi: Oncology Pharmaceuticals Annual Revenue, 2018-2020
Table 107 : Takeda Pharmaceutical Co, Ltd.: Oncology Pharmaceutical Product Portfolio
Table 108 : Takeda Pharmaceutical Co. Ltd.: Oncology Pharmaceutical Revenue, 2019-2021
Table 109 : New Cancer Cases in the U.S., by Age Group, 2018
Table 110 : Trends in Per Capita Real GDP Growth, by OECD Region, 2012-2016
Table 111 : Glossary of Terms Used in Women’s Health Therapeutics
Table 112 : Acronyms Used in Women’s Health Therapeutics


List of Figures
Summary Figure A : Global Market for Women’s Health Therapeutics, by Disease Area, 2020-2026
Summary Figure B : Global Market for Women’s Health Therapeutics, by Region, 2020-2026
Figure 1 : Distribution of Global Elderly Population, by Age Group and Sex, 2020
Figure 2 : Distribution of Global Elderly Population, by Age Group and Sex, 2050
Figure 3 : Funding for Research in Women’s Health, by Disease Condition/Category, 2014-2016
Figure 4 : Funding for Research in Women’s Health, 2014-2016
Figure 5 : Distribution of Insurance Coverage in the U.S., by Type of Healthcare Provider, 2014
Figure 6 : Global Market for Women’s Health Therapeutics, 2018-2026
Figure 7 : Global Market Shares of Women’s Health Therapeutics, by Disease Area, 2020
Figure 8 : Global Market Shares of Women’s Health Therapeutics, by Disease Area, 2026
Figure 9 : Global Market for Menopause Therapeutics, 2020-2026
Figure 10 : Global Market for Menopause Therapeutics, by Region, 2020-2026
Figure 11 : Rate of Hospitalization for Osteoporosis in Australia, by Age Group, 2015-2016
Figure 12 : Global Market for Postmenopausal Osteoporosis Therapeutics, 2020-2026
Figure 13 : Global Market for Postmenopausal Osteoporosis Therapeutics, by Region, 2020-2026
Figure 14 : Global Market for Endometriosis Therapeutics, 2018-2026
Figure 15 : Global Market for Endometriosis Therapeutics, by Region, 2020-2026
Figure 16 : Global Market for PCOS Therapeutics, 2018-2026
Figure 17 : Global Market for PCOS Therapeutics, by Region, 2018-2026
Figure 18 : Global Market for Breast Cancer Therapeutics, 2018-2026
Figure 19 : Global Market for Breast Cancer Therapeutics, by Region, 2020-2026
Figure 20 : Global Market for Women’s Health Therapeutics, by Region, 20202026
Figure 21 : North American Market Shares of Women’s Health Therapeutics, by Country, 2020
Figure 22 : North American Market for Women’s Health Therapeutics, 2018-2026
Figure 23 : North American Market Shares of Women’s Health Therapeutics, by Disease Area, 2020
Figure 24 : North American Market for Women’s Health Therapeutics, by Country, 2020-2026
Figure 25 : U.S. Market for Women’s Health Therapeutics, 2018-2026
Figure 26 : Canadian Market for Women’s Health Therapeutics, 2018-2026
Figure 27 : Mexican Market for Women’s Health Therapeutics, 2018-2026
Figure 28 : European Market for Women’s Health Therapeutics, by Country, 2020-2026
Figure 29 : European Market Shares of Women’s Health Therapeutics, by Country, 2020
Figure 30 : European Market for Women’s Health Therapeutics, 2018-2026
Figure 31 : European Market Shares of Women’s Health Therapeutics, by Disease Area, 2020
Figure 32 : U.K. Market for Women’s Health Therapeutics, 2018-2026
Figure 33 : German Market for Women’s Health Therapeutics, 2018-2026
Figure 34 : French Market for Women’s Health Therapeutics, 2018-2026
Figure 35 : Spanish Market for Women’s Health Therapeutics, 2018-2026
Figure 36 : Italian Market for Women’s Health Therapeutics, 2018-2026
Figure 37 : Rest of the European Market for Women’s Health Therapeutics, 2018-2026
Figure 38 : Asia-Pacific Market for Women’s Health Therapeutics, 2018-2026
Figure 39 : Asia-Pacific Market Shares of Women’s Health Therapeutics, by Disease Area, 2020
Figure 40 : Asia-Pacific Market Shares of Women’s Health Therapeutics, by Disease Area, 2020
Figure 41 : Asia-Pacific Market for Women’s Health Therapeutics, by Disease Area, 2020-2026
Figure 42 : Chinese Market for Women’s Health Therapeutics, 2018-2026
Figure 43 : Japanese Market for Women’s Health Therapeutics, 2018-2026
Figure 44 : Indian Market for Women’s Health Therapeutics, 2018-2026
Figure 45 : South Korean Market for Women’s Health Therapeutics, 2018-2026
Figure 46 : Rest of Asia-Pacific Countries’ Market for Women’s Health Therapeutics, 2018-2026
Figure 47 : RoW Market for Women’s Health Therapeutics, by Sub-region, 2018-2026
Figure 48 : RoW Market Shares of Women’s Health Therapeutics, by Subregion, 2020
Figure 49 : RoW Market for Women’s Health Therapeutics, 2018-2026
Figure 50 : RoW Market Shares of Women’s Health Therapeutics, by Disease Area, 2020
Figure 51 : South American Market for Women’s Health Therapeutics, 2018-2026
Figure 52 : South American Market Shares of Women’s Health Therapeutics, by Disease Area, 2020
Figure 53 : Middle East and African Market for Women’s Health Therapeutics, 2018-2026
Figure 54 : Global Market Shares of Women’s Health Therapeutics, by Company, 2020
Figure 55 : AbbVie: Hematologic Oncology Annual Revenue, 2018-2020
Figure 56 : AbbVie Inc.: Revenue Share, by Country, 2020
Figure 57 : Allergan plc: Revenue Share, by Business Segment, 2017
Figure 58 : Amgen Oncology Pharmaceuticals: Annual Revenue, 2018-2020
Figure 59 : AstraZeneca’s Oncology Segment: Annual Revenue, 2018-2020
Figure 60 : Bayer AG: Oncology Pharmaceutical Annual Revenue, 2018-2020
Figure 61 : Bayer AG: Revenue Share, by Region, 2018
Figure 62 : Bayer AG: Revenue Share, by Business Segment, 2018
Figure 63 : Bristol-Myers Squibb Oncology Pharmaceuticals: Annual Revenue, 2018-2020
Figure 64 : Daiichi Sankyo Co. Ltd.: R&D Expenditure, 2014-2016
Figure 65 : Daiichi Sankyo Co. Ltd.: Revenue Share, by Business Segment, 2018
Figure 66 : Eli Lilly and Co.: Revenue Share, by Business Segment, 2018
Figure 67 : Eli Lilly and Co.: Oncology Annual Revenue, 2018-2020
Figure 68 : Roche: Oncology Annual Revenue, 2018-2020
Figure 69 : Gilead Sciences Inc.: Oncology Pharmaceutical Annual Revenue, 2018-2020
Figure 70 : Johnson & Johnson’s Oncology Segment: Annual Revenue, 2018-2020
Figure 71 : Johnson and Johnson Services Inc.: Revenue Share, by Business Segment, 2018
Figure 72 : Johnson & Johnson Services Inc.: Revenue Share, by Region, 2018
Figure 73 : Merck & Co. Inc.: Revenue Share, by Business Segment, 2018
Figure 74 : Merck & Co. Inc.: Revenue Share, by Region, 2018
Figure 75 : Merck & Co.’s Oncology Pharmaceutical: Annual Revenue, 2018-2020
Figure 76 : Novartis’s Oncology Segment: Annual Revenue, 2018-2020
Figure 77 : Novo Nordisk: Revenue Share, by Region, 2018
Figure 78 : Novo Nordisk: Revenue Share, by Business Segment, 2018
Figure 79 : Pfizer Inc.: Oncology Segment: Annual Revenue, 2018-2020
Figure 80 : Pfizer Inc.: Revenue Share, by Region, 2018
Figure 81 : Pfizer Inc.: Revenue Share, by Business Segment, 2018
Figure 82 : Sanofi: Oncology Pharmaceuticals, Annual Revenue, 2018-2020
Figure 83 : Takeda Pharmaceutical: Oncology Annual Revenue, 2019-2021
Figure 84 : Rate of New Cancer Cases in the U.S., by Age Group, 2018
Note: Product cover images may vary from those shown
  • Abbvie Inc.
  • Amgen Inc.
  • Asahi Kasei
  • Astrazeneca plc
  • Bayer AG
  • Bristol-Myers Squibb
  • Daiichi Sankyo Co. Ltd.
  • Eisai
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Merck Kgaa
  • Novartis AG
  • Novo Nordisk
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown